These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effects of postovulatory estradiol benzoate administration on women's ovarian function.
    Author: Oriol-Bosch A, Cortés J.
    Journal: Fertil Steril; 1975 May; 26(5):405-12. PubMed ID: 1126465.
    Abstract:
    The effects of postovulatory estradiol benzoate (EB) administration were studied in six women having normal biphasic, presumably ovulatory, menstrual cycles. EB was administered intramuscularly at dose levels of 0.5 and 10 mg daily for 5 consecutive days. The study covered a total of 30 cycles; parameters studied were basal body temperature, urinary excretion of estrogens and pregnanediol, and characteristics of cervical mucus. EB had no effect on the length of the luteal phase nor on urinary pregnanediol excretion, but a dose of 10 mg/day caused a significant prolongation of the next follicular phase. The elevated estrogen excretion observed at the end of the cycle supports the hypothesis that gestagenic deprivation causes menstrual bleeding. The effect of postovulatory administration of estradiol benzoate on the functional life of the corpus luteum was investigated in 6 women. Either .5 or 10 mg of estradiol benzoate was injected im each day for 5 consecutive days beginning on the 1st day of basal body temperature rise. Treatment began on the average on Day 17.5 of the cycle, 1-4 days after the probable day of ovulation. A shortening of the luteal phase was seen with both dosage levels. Prolongation of the follicular phase was noted in the 10 mg/day group but not in the .5 mg group. Some of the administered estradiol benzoate was detectable in the urine; about 20% in the 5 mg doses, about 12% in the 10 mg patients. A rebound phenomenon in pregnanediol excretion was observed after estradiol benzoate treatment. It was concluded that menstrual bleeding is strongly related to a decrease in pregnanediol excretion. It was suggested that this reflects failure of the luteal phase to maintain progesterone secretion but such failure appears independent of the bioavailability of estrogens.
    [Abstract] [Full Text] [Related] [New Search]